Skip to content

Cancer Health Center

Font Size

Childhood Hodgkin Lymphoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Diagnosis and Staging

Table 2. Criteria Used for the Classification of Risk Groups in Childhood Hodgkin Lymphoma Clinical Trialsa

TrialLow RiskIntermediate RiskHigh Risk
E = extralymphatic.
a Adapted from Kelly.[16]
Children's Oncology Group
AHOD0031[17] IA bulk or E; IB; IIA bulk or E; IIB; IIIA, IVA 
AHOD0431[18]IA, IIA with no bulk  
AHOD0831  IIIB, IVB
C5942[19]IA, IB, IIA with no bulk, no hilar nodes and <4 sitesIA, IB, IIA with bulk, hilar nodes or ≥4 sites; IIIIV
C59704[20]  IIB/IIIB with bulk, IV
P9425/P9426[21]IA, IIA with no bulkIB, IIA, IIIA1 with bulk; IIIA2IIB, IIIB, IV
 
German Multicenter/Euronet
GPOH-HD 95; GPOH-HD 2002;PHL-C1[3,22,23]1A/B, IIAIE A/B;IIE A; IIB; IIIAIIE B; IIIE A/B; IIIB; IV
 
Stanford/St. Jude/Dana-Farber Cancer Institute Consortium
HOD05 IB, IIIA, IA/IIA with E, ≥3 sites or bulk 
HOD08IA, IIA with no bulk, E and <3 sites  
HOD99  IIB, IIIB, IV

Although all major research groups classify patients according to clinical criteria, such as stage and presence of B symptoms, extranodal involvement, or bulky disease, comparison of outcomes across trials is further complicated because of differences in how these individual criteria are defined.

Response Assessment

Further refinement of risk classification may be performed through assessment of response after initial cycles of chemotherapy or at its completion.

Interim response assessment

The interim response to initial therapy, which may be assessed on the basis of volume reduction of disease, functional imaging status, or both, is an important prognostic variable in both early- and advanced-stage pediatric Hodgkin lymphoma.[24,25] Definitions for interim response are variable and protocol specific, but can range from volume reductions of greater than 50% to the achievement of a complete response with a volume reduction of greater than 95% by anatomic imaging or resolution of FDG-PET avidity.[3,18,21]

The rapidity of response to early therapy has been used in risk stratification to tailor therapy in an effort to augment therapy in higher-risk patients or to reduce the late effects while maintaining efficacy.

1|2|3|4|5|6
Next Article:

Today on WebMD

Colorectal cancer cells
New! I AM Not Cancer Facebook Group
Lung cancer xray
See it in pictures, plus read the facts.
 
sauteed cherry tomatoes
Fight cancer one plate at a time.
Ovarian cancer illustration
Real Cancer Perspectives
 
Jennifer Goodman Linn self-portrait
Blog
what is your cancer risk
HEALTH CHECK
 
colorectal cancer treatment advances
Video
breast cancer overview slideshow
SLIDESHOW
 
prostate cancer overview
SLIDESHOW
lung cancer overview slideshow
SLIDESHOW
 
ovarian cancer overview slideshow
SLIDESHOW
Actor Michael Douglas
Article